Victory Capital Management Inc. Sells 46,430 Shares of Halozyme Therapeutics, Inc. $HALO

Victory Capital Management Inc. trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 623,029 shares of the biopharmaceutical company’s stock after selling 46,430 shares during the quarter. Victory Capital Management Inc.’s holdings in Halozyme Therapeutics were worth $45,693,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Elo Mutual Pension Insurance Co increased its position in shares of Halozyme Therapeutics by 46.4% during the 3rd quarter. Elo Mutual Pension Insurance Co now owns 21,555 shares of the biopharmaceutical company’s stock valued at $1,581,000 after purchasing an additional 6,835 shares during the last quarter. Fisher Asset Management LLC grew its position in Halozyme Therapeutics by 7.6% during the third quarter. Fisher Asset Management LLC now owns 410,892 shares of the biopharmaceutical company’s stock valued at $30,135,000 after buying an additional 29,147 shares during the period. Handelsbanken Fonder AB grew its position in Halozyme Therapeutics by 82.9% during the third quarter. Handelsbanken Fonder AB now owns 388,369 shares of the biopharmaceutical company’s stock valued at $28,483,000 after buying an additional 176,000 shares during the period. Diversify Wealth Management LLC grew its position in shares of Halozyme Therapeutics by 3.8% during the 3rd quarter. Diversify Wealth Management LLC now owns 19,750 shares of the biopharmaceutical company’s stock valued at $1,448,000 after acquiring an additional 722 shares during the period. Finally, Intech Investment Management LLC raised its holdings in shares of Halozyme Therapeutics by 46.0% in the 3rd quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock worth $10,903,000 after purchasing an additional 46,850 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the sale, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $53,947,690.28. The trade was a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 62,000 shares of company stock valued at $4,545,200. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Trading Up 0.0%

NASDAQ:HALO opened at $67.37 on Friday. The company has a fifty day moving average of $72.66 and a 200 day moving average of $70.73. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The firm has a market capitalization of $7.95 billion, a P/E ratio of 27.06, a P/E/G ratio of 0.27 and a beta of 0.98.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). The business had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The company’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 EPS. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on HALO shares. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, January 29th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Wells Fargo & Company raised their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $78.56.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.